Target Name: MIR219A1
NCBI ID: G407002
Other Name(s): MIRN219-1 | hsa-miR-219a-1-3p | mir-219a-1 | microRNA 219a-1 | hsa-miR-219a-5p | MIR219-1 | mir-219 | MicroRNA 219a-1 | MRI219-1 | hsa-mir-219a-1

MIR219A1: A Non-Coding RNA Molecule as A Cancer and Biomarker Target

MIR219A1 (MIRN219-1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. MIR219A1 is a key regulator of cell proliferation and has been shown to play a role in the development and progression of various diseases, including cancer.

The MIR219A1 gene was identified through a combination of genomic and transcriptomic approaches. The gene was found to be highly expressed in a variety of tissues and cells, including cancer cells, and was shown to be involved in the regulation of cell cycle progression.

While the exact mechanism of how MIR219A1 contributes to cancer development is not yet fully understood, several studies have suggested that it may play a role in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. MIR219A1 has been shown to regulate the activity of a protein called SMAD, which is involved in the regulation of the blood-brain barrier.

Another potential mechanism for the involvement of MIR219A1 in cancer development is its role in cell signaling pathways. MIR219A1 has been shown to be involved in the regulation of several signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cell growth and survival.

In addition to its potential role in cancer development, MIR219A1 has also been shown to be involved in the regulation of normal cellular processes. For example, MIR219A1 has been shown to play a role in the regulation of cell division, and has been shown to be involved in the maintenance of cellular stability.

Given the potential involvement of MIR219A1 in cancer development and normal cellular processes, it is an attractive target for drug development. Several compounds have been shown to interact with MIR219A1 and have been tested in animal models of cancer. However, the lack of human studies with these compounds makes it difficult to determine their safety and efficacy.

In conclusion, MIR219A1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Further research is needed to fully understand its role in cancer development and normal cellular processes.

Protein Name: MicroRNA 219a-1

More Common Targets

MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143